Panel Discussion: Redefining Biomarker Discovery with AI: Integrating Multi-Omic & Image-Based Insights for Smarter Oncology Trials
- What are the critical steps in designing end-to-end AI pipelines that integrate computational pathology, RNA-seq, and clinical metadata?
- How can AI teams define clear success metrics for model validation, accuracy, reproducibility, or clinical actionability?
- How will foundation models and generative AI redefine how we integrate histological and omic modalities?
- How can partnerships between pharma, AI technology providers, and academic pathology groups accelerate validation and adoption?